Skip to content

Study · In vitro (cells) · 2025

6 results

Investigating the P53-dependent anti-cancer effect of ibutamoren in human cancer cell lines.

Abdul Ghafoor N, Rasuli S, Tanriverdi Ö, Yildiz A

Basic & clinical pharmacology & toxicology1 Jan 2025

PMID39668330 (opens in a new tab)DOI10.1111/bcpt.14111 (opens in a new tab)PepBankPUB-39668330
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Efficacy outcome

    Ibutamoren reduced viability in immortalized human cancer cells with a functional MDM2-p53 pathway.

    In plain wordsIn cells with a functional MDM2-p53 pathway, ibutamoren reduced cancer cell viability.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    DecreaseCell viability with functional pathway
    Study

    humann: not reported in source

    immortalized human cancer cell lines with functional MDM2-p53 pathway
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vitro experiments demonstrated that IBU treatment reduced the viability of immortalized cancer cell lines with a functional MDM2-p53 pathway but not in cell lines where this pathway harboured damaging mutations.
    1 context sentence
    Title · context
    Investigating the P53-dependent anti-cancer effect of ibutamoren in human cancer cell lines.
  2. 02LabIn vitro (cells)Efficacy outcome

    Ibutamoren did not reduce viability in cancer cell lines with damaging MDM2-p53 pathway mutations.

    In plain wordsIn cells with damaging MDM2-p53 mutations, ibutamoren did not reduce cancer cell viability.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    No significant changeCell viability with mutated pathway
    Study

    humann: not reported in source

    immortalized human cancer cell lines with damaging MDM2-p53 mutations
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vitro experiments demonstrated that IBU treatment reduced the viability of immortalized cancer cell lines with a functional MDM2-p53 pathway but not in cell lines where this pathway harboured damaging mutations.
    1 context sentence
    Title · context
    Investigating the P53-dependent anti-cancer effect of ibutamoren in human cancer cell lines.
  3. 03LabIn vitro (cells)Mechanism

    Ibutamoren altered expression of two unspecified p53 target genes in cells with wild MDM2-p53 pathways.

    In plain wordsIn cells with wild MDM2-p53 pathways, ibutamoren changed expression of two unnamed p53 target genes.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    Direction not reportedp53 target gene expression
    Study

    humann: not reported in source

    human cancer cell lines with wild MDM2-p53 pathways
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    This trend was further supported by RT-qPCR analysis, which showed differential expression of two p53 target genes upon IBU treatment in cell lines with wild MDM2-p53 pathways but not in those harbouring damaging mutations.
    1 context sentence
    Title · context
    Investigating the P53-dependent anti-cancer effect of ibutamoren in human cancer cell lines.
  4. 04LabIn vitro (cells)Mechanism

    Ibutamoren did not alter the reported p53 target gene expression in cells with damaging MDM2-p53 mutations.

    In plain wordsIn cells with damaging MDM2-p53 mutations, ibutamoren did not change the reported p53 target gene expression.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    No significant changep53 target gene expression with mutations
    Study

    humann: not reported in source

    human cancer cell lines with damaging MDM2-p53 mutations
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    This trend was further supported by RT-qPCR analysis, which showed differential expression of two p53 target genes upon IBU treatment in cell lines with wild MDM2-p53 pathways but not in those harbouring damaging mutations.
    1 context sentence
    Title · context
    Investigating the P53-dependent anti-cancer effect of ibutamoren in human cancer cell lines.

Studies that did not test the peptide alone2

In this study, MK-677 (ibutamoren) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking MK-677 (ibutamoren).

  1. 05Computer modelNot a test of MK-677 (ibutamoren) aloneIn silicoActivity measurement

    Molecular modelling predicted a low IC50 for ibutamoren inhibition of MDM2.

    In plain wordsComputer models predicted that ibutamoren inhibits MDM2 at a low concentration.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    Not applicablePredicted MDM2 inhibition
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    In silico analyses utilizing molecular modelling revealed that IBU has a low IC50 for MDM2 inhibition and favourably binds to the p53-binding pocket of MDM2.

    In this study, MK-677 (ibutamoren) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MK-677 (ibutamoren).

  2. 06Computer modelNot a test of MK-677 (ibutamoren) aloneIn silicoMechanism

    Molecular modelling predicted favourable ibutamoren binding to the p53-binding pocket of MDM2.

    In plain wordsComputer models predicted favourable ibutamoren binding to the p53-binding site of MDM2.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    Not applicableMDM2 binding
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    In silico analyses utilizing molecular modelling revealed that IBU has a low IC50 for MDM2 inhibition and favourably binds to the p53-binding pocket of MDM2.

    In this study, MK-677 (ibutamoren) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MK-677 (ibutamoren).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.